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More than 25 yr ago, IL-2 was identifi  ed as 
an autocrine secretory product required for 
long-term culture of helper (CD4+) T cells 
(1). Subsequently, the importance of IL-2 has 
been affi     rmed, but its eff   ects on these cells, 
whether direct or indirect, are more diverse 
and complex than initially proposed. Early 
  reports demonstrated that IL-2 promotes adap-
tive immunity by augmenting T cell pro-
liferation, survival, and effector (Th1/Th2) 
diff  er  entiation (2, 3). It was later established 
that by   programming them for apoptosis, IL-2 
also participates in the contraction of infl  am-
matory responses, and, more recently, it has 
been shown to promote expansion of regula-
tory T (T reg) cells, a lineage that is critical for 
maintaining self-tolerance (4, 5). Due to these 
latter eff  ects, IL-2 and IL-2 receptor–defi  cient 
mice exhibit a complex autoimmune pheno-
type characterized by multi-organ infl  amma-
tion, a lack of T reg cells, and an accumulation 
of autoreactive T cells (4). However, despite a 
growing appreciation for these antiinfl  amma-
tory properties, only the stimulatory capacity 
of IL-2 has been considered for therapeutics, 
most notably for promoting T cell expansion 
and function in patients with advanced cancers 
or AIDS (6, 7).
Given the paucity of antigen-specifi  c T cells 
at the onset of an immune response and the 
fact that IL-2 is a potent growth factor in vitro, 
it has long been accepted that IL-2 is neces-
sary for clonotypic expansion (2). Consistent 
with this notion, IL-2 is one of the fi  rst pro-
ducts of activated CD4+ T cells and is required 
for the development, proliferation, and sur-
vival of antigen-specific effector (Th1/Th2) 
and T reg cell populations in vivo (2, 3, 8). 
Still, although it is known that IL-2–secreting 
T cells are pluripotent, capable of diff  eren  tiating 
into multiple lineages (Th1/Th2/T reg cells) 
(9, 10), their appearance is short-lived and 
the molecular mechanisms underlying the tran-
sient nature of this response remain poorly 
  defi  ned (11).
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Although required for many fundamental immune processes, ranging from self-tolerance 
to pathogen immunity, interleukin (IL)-2 production is transient, and the mechanisms 
underlying this brevity remain unclear. These studies reveal that helper T cell IL-2 produc-
tion is limited by a classic negative feedback loop that functions autonomously or in 
collaboration with other common 𝗄 chain (IL-4 and IL-7) and IL-6/IL-12 family cytokines 
(IL-12 and IL-27). Consistent with this model for cytokine-dependent regulation, they 
also demonstrate that the inhibitory effect can be mediated by several signal transducer 
and activator of transcription (STAT) family transcription factors, namely STAT5, STAT4, 
and STAT6. Collectively, these fi  ndings establish that IL-2 production is limited by a network 
of autocrine and paracrine signals that are readily available during acute infl  ammatory 
responses and, thus, provide a cellular and molecular basis for its transient pattern 
of expression.
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RESULTS AND DISCUSSION
Helper T cell IL-2 production is limited 
by a classic negative feedback loop
To investigate the kinetics of IL-2 production, an in vitro 
model of T cell diff  erentiation was used. Naive polyclonal 
T cells were labeled with CFSE, a vital dye that allows pro-
liferative history to be visualized, activated with TCR and 
CD28-specifi  c agonist antibodies, and, on successive days 
  after stimulation, intracellular cytokine staining was used to 
quantify IL-2. The peak in IL-2 responses was noted during 
the fi  rst 24 h of culture, an early time point that preceded 
the onset of cell division and eff  ector cytokine production 
(Fig. 1 A and unpublished data). At later intervals, most cells 
had proliferated and the percentage of IL-2+ events declined 
gradually: a twofold reduction after 48 h and a threefold drop 
at 72 h (Fig. 1, A–C). These data are consistent with many 
previous reports in demonstrating that helper T cells produce 
IL-2 quickly but transiently (9, 11).
The preceding studies imply that IL-2 production wanes 
as T cells divide and diff  erentiate, but they do not provide a 
rationale for this phenomenon. Given that IL-2 was rapidly 
secreted and, consequently, was abundant in these cultures, it 
was postulated that IL-2 itself might suppress IL-2  production. 
To investigate that hypothesis, IL-2 was neutralized with 
a monoclonal anti–IL-2 antibody (mAb) and kinetic analysis 
was performed as before. Depletion of IL-2 had little eff  ect 
on IL-2 production during the fi  rst 24 h in culture, but, 
  remarkably, this treatment abrogated subsequent reductions 
in IL-2+ events and in the amount of cytokine produced 
per cell (mean fl  uorescence intensity [MFI]; Fig. 1, A–C). 
Consistent with changes in protein expression, IL-2 mRNA 
levels rose dramatically when IL-2 was neutralized (Fig. 1 D) 
and, fi  ttingly, there was a dose-dependent decline in the 
  percentage of IL-2+ cells, IL-2 MFI, and IL-2 mRNA when 
IL-2–defi  cient cultures were supplemented with recombi-
nant human cytokine (Fig. 2, A–C). IL-2 responses were 
unaff  ected when CD25+ T reg cells were depleted from 
IL-2–suffi   cient or –defi  cient cultures, indicating that despite 
a well-established role in suppressing IL-2 production (4, 10), 
they have little infl  uence during the short-term assays used 
here (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20061198/DC1). Collectively, these studies imply 
that IL-2 limits itself directly via a classic negative feedback 
loop, not through eff  ects on T reg cells.
To confi  rm that IL-2–dependent inhibition is applica-
ble during physiological modes of activation, OVA-specifi  c 
Figure 1.  IL-2 is required for the natural decay in IL-2 production 
during helper T cell differentiation. (A–D) Polyclonal CD4+ T cells were 
CFSE labeled, stimulated with anti-CD3/anti-CD28, and cultured with or 
without anti–IL-2 mAb. (A–C) After 24, 48, or 72 h, cells were stained for 
surface CD4 and intracellular IL-2 (n = 6; fi  ve experiments pooled in B). 
(D) Cells were collected at 48 h (no PMA/Iono/BFA), and IL-2 mRNA was 
quantifi  ed by real-time PCR. (E) Monoclonal DO11.10+ CD4+ T cells were 
CFSE labeled and stimulated with antigen, soluble anti-CD28 mAb, and 
syngeneic APCs (±anti–IL-2 mAb). IL-2 production was measured after 
48 or 96 h. (A–D) Only CD4+ (A and C) or CD4+ DO11.10+ (E) events are 
shown. RT-PCR data are pooled from fi  ve separate experiments.
Figure 2.  Common 𝗄 chain cytokines can suppress helper T cell 
IL-2 production. (A–C) CFSE-labeled CD4+ T cells were cultured with anti-
murine IL-2 mAb and supplemented with recombinant human IL-2 (left 
to right: 1, 10, 50, and 100 U/ml). As in Fig. 1, fl  ow cytometry and RT-PCR 
were used to quantify IL-2 production at 72 and 48 h, respectively (n = 3; 
three experiments pooled in B and C). (D–H) IL-2 production was measured 
after CD4+ T cells were cultured with recombinant IL-4, IL-7, or IL-15 
(±anti–IL-2 mAb; 48 h; n = 3; three experiments pooled in D–F). 
(A–H) Only CD4+ events are shown.JEM VOL. 204, January 22, 2007  67
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CD4+ T cells (DO11.10) were stimulated with OVA-pulsed 
APCs and IL-2 production was monitored. As with the poly-
clonal studies, IL-2 production was transient in this mono-
clonal population and, more importantly, the decline in 
cytokine production was dependent on IL-2 (Fig. 1 E). In 
concert with the above fi  ndings, these data support the idea 
that IL-2 itself is responsible for a “natural” decline in IL-2 
production during nascent helper T cell responses.
Common 𝗄 chain cytokines limit helper T cell 
IL-2 production
IL-2 is the founder of a cytokine family whose members use 
the common γ chain as a shared component of their receptor 
complexes (12). Because common γ chain cytokines can 
have analogous functions in helper T cells, experiments were 
performed to determine whether IL-4, IL-7, or IL-15 sup-
presses IL-2 production. Similar to previous reports (13), 
these studies demonstrate that IL-4 is a potent inhibitor of 
IL-2 production, prompting signifi  cant reductions in IL-2+ 
events, IL-2 MFI, and IL-2 mRNA (Fig. 2, D–H). Although 
better known for its eff  ects on memory cells (14), IL-7 also 
inhibited IL-2 production, albeit to a lesser extent than IL-4 
(Fig. 2, D–H). On the other hand, despite sharing two receptor 
chains with IL-2 (3), IL-15 had little eff  ect on this process, 
suggesting that the analogy cannot be extended to all   common 
γ chain family members (Fig. 2, D–H).
The preceding studies demonstrate that IL-2 and IL-4 can 
each suppress helper T cell IL-2 production. Because both 
can activate STAT5 (15), the signature transcription factor of 
common γ chain cytokines (12), it was reasoned that their 
shared ability to inhibit IL-2 production could be mediated 
through this pathway. To test that hypothesis, cytokine-
  dependent IL-2 inhibition was compared between WT CD4+ 
T cells and those derived from mice lacking STAT5a/b in 
the T cell compartment (16). From these studies, it was clear 
that STAT5−/− cells produced more IL-2 than WT counter-
parts, presenting almost 10 times as many IL-2+ events and 
a sixfold increase in IL-2 MFI at 48 h after stimulation (Fig. 3, 
A and B, and Fig. S2, which is available at http://www.jem
.org/cgi/content/full/jem.20061198). Moreover, although 
IL-2 production was comparable between WT and STAT5−/− 
cells when IL-2 was neutralized, the human cytokine could 
only suppress in the former group, thus formally establishing 
that the negative feedback loop is dependent on STAT5 
(Fig. 3, A and B, and Fig. S2). In fact, STAT5−/− CD4+ 
T cells produced similar levels of IL-2 at 24 and 72 h after 
stimulation, demonstrating that, unlike for WT counterparts, 
IL-2 production was not transient in the absence of this tran-
scription factor (Fig. S2).
IL-2 production is inhibited by Th1- and 
Th2-polarizing factors
The preceding studies demonstrate that, similar to IL-2, the 
ability of IL-4 to suppress IL-2 production was diminished in 
STAT5−/− T cells. However, it was also noted that IL-4 
could still prompt small, yet consistent reductions in IL-2+ 
events, and it remained possible that IL-4 could use addi-
tional signaling pathways to suppress. One obvious candidate 
for these activities was STAT6, the transcription factor that 
drives its ability to promote Th2 responses (17). To assess 
whether the culture conditions used here triggered STAT6 
activation, WT CD4+ T cells were stimulated with anti-
CD3/CD28 and fl  ow cytometry was used to detect the ac-
tive, phosphorylated form of this protein. As expected, naive 
cells were devoid of phospho-STAT6 and remained so dur-
ing the fi  rst 2 h in culture. However, phospho-STAT6 was 
clearly evident at 24 h after stimulation, suggesting that acti-
vating factors did become available (Fig. 4 A). To determine 
whether STAT6 participates in suppressing IL-2, cytokine 
production was compared between WT and STAT6−/− 
CD4+ T cells. After 48 h in culture, STAT6−/− cells pro-
duced twice as much IL-2 as WT counterparts (Fig. 4, B–D). 
Moreover, although IL-2 production was similar when IL-2 
was depleted, indicating that IL-2/STAT5-dependent inhi-
bition was functional in both groups, the ability of exogenous 
IL-4 to suppress was indeed lost in STAT6−/− cells (Fig. 4, 
B–D). Together with the above experiments, these fi  ndings 
establish that STAT5 and STAT6 are required for IL-4 to 
  inhibit IL-2 production and, given that a considerable loss of 
activity is observed when either transcription factor is   deleted, 
they are likely to cooperate in this process.
Given the role of IL-2/STAT5 in promoting Th2 re-
sponses (8), it is likely that anti–IL-2 mAb greatly diminished 
IL-4 production in the culture system used here. Conse-
quently, it may be reasoned that the rise in IL-2 production 
Figure 3.  STAT5 is required for IL-2 and IL-4 to suppress IL-2 
production. (A–D) CD4+ T cells were isolated from either WT mice 
(STAT5+/+) or those lacking STAT5a/b in T cells (STAT5−/−). Cells were 
  cultured with or without anti–IL-2 mAb and, where noted, hIL-2, IL-4, or 
IL-12 was added. Only CD4+ events are shown (n = 3; compiled in Fig. S2).68  IL-2 PRODUCTION IS LIMITED BY CYTOKINE/STAT SIGNALS | Villarino et al.
associated with blocking IL-2 could be a secondary conse-
quence of its eff  ects on IL-4, itself a potent inhibitor. To ad-
dress that issue, IL-2 production was measured after WT 
CD4+ T cells were cultured with or without neutralizing 
anti–IL-4 mAb. Consistent with the idea that helper T cells 
are a primary source of IL-4, depletion of this cytokine had at 
least two eff  ects: an increase in the percentage of IFN-γ+ 
cells and, relevant to this work, a rise in IL-2+ cells (unpub-
lished data and Fig. 4 E). These data affi   rm that autocrine IL-4 
production can have a signifi  cant impact on IL-2 responses 
and imply that IL-4 is likely responsible for the robust STAT6 
activation noted in the cultures (Fig. 4 A). However, because 
the eff  ect of anti–IL-2 mAb was more profound than that 
of anti–IL-4 mAb, a reduction in IL-4 cannot wholly 
account for the effi   cacy of the former. Furthermore, there 
was a cumulative eff  ect when both cytokines were removed, 
suggesting that they may cooperate in regulating IL-2 pro-
duction (Fig. 4 E).
Although IL-2 is known to promote Th1 and Th2 re-
sponses, it is traditionally considered a Th1 cytokine (17). In 
contrast to this model, a recent report has shown that IL-2 
production is inhibited by IL-12, a member of the IL-6/IL-12 
cytokine family that is key in promoting Th1 diff  erentiation 
(18). This present study supports these fi  ndings by demon-
strating that IL-12 can prompt substantial reductions in IL-2+ 
events and IL-2 MFI (Fig. 4 H). This inhibitory property was 
not dependent on STAT5 or STAT6 (Fig. 3 and unpublished 
data) but, as shown previously (18), was mediated through 
STAT4, the same transcription factor that it uses to promote 
Th1 responses (19). IL-12 could not suppress IL-2 produc-
tion in STAT4−/− cells, and, even when exogenous IL-12 
was not added, it was clear that lacking STAT4 predisposed 
them to enhanced IL-2 production (Fig. 4, H and I). Consis-
tent with the latter point, STAT4 activation was confi  rmed 
by fl  ow cytometry (Fig. 4 F), but because neutralizing IL-12 
has little eff  ect on IL-2 production (unpublished data), the 
STAT4 stimulus in the nonpolarizing cultures remains 
  unknown. Nevertheless, taken with the above results, these 
studies imply that, despite prevailing dogma, IL-2 production 
can be limited by factors traditionally associated with polariz-
ing both Th1 and Th2 responses.
IL-2 can suppress helper T cell IL-2 production 
after immunization
To determine whether IL-2 can suppress in vivo IL-2 re-
sponses, DO11.10 CD4+ T cells were transferred into WT 
mice that were then immunized with OVA-pulsed DCs and 
treated with either IL-2 or PBS. At 5 d after immunization, 
both groups displayed a signifi  cant increase in the overall cel-
lularity of lymphoid organs (LN/spleen), thereby confi  rming 
the effi     cacy of the DCs as immunogens. This eff  ect  was 
slightly greater in IL-2–treated mice than in control animals, 
but the absolute numbers of antigen-specifi  c T cells remained 
comparable, suggesting that this dose of IL-2 did not lead to 
unwarranted T cell expansion or depletion (Fig. 5 A). How-
ever, as expected, the IL-2 regimen did have two signifi  cant 
eff   ects on DO11+CD4+ cells: it enhanced expression of 
CD25, a known IL-2/STAT5 target (2, 12), and greatly re-
duced their ability to produce IL-2 during ex vivo recall as-
says (Fig. 5, B–E). Given that the percentage of FoxP3+ cells 
Figure 4.  Helper T cell IL-2 production is limited by Th1- and 
Th2-polarizing factors. (A) CD4+ T cells were stimulated with anti-CD3 
and anti-CD28. At 15 min, 2 h, and 24 h after activation, cells were fi  xed 
and permeabilized, and phospho-STAT6 was detected by fl  ow cytometry 
(not shown: 5, 30, and 60 min; n = 2). (B–D) WT or STAT6−/− CD4+ T cells 
were cultured as described above (±anti–IL-2 mAb) and, where noted, 
IL-4 was added (n = 2: two experiments pooled in B). (E) CD4+ T cells were 
cultured with or without anti–IL-4 mAb (±anti–IL-2 mAb), and IL-2 pro-
duction was monitored. (F) Phospho-STAT4 was measured after cells were 
stimulated and stained as in A (n = 2). (G–I) WT or STAT4−/− CD4+ T cells 
were cultured with or without IL-12 (n = 3: three experiments pooled in G). 
(A–I) Only CD4+ events are shown. JEM VOL. 204, January 22, 2007  69
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was similar in both groups, these eff  ects were not likely me-
diated through IL-2–dependent T reg cell expansion (un-
published data and Fig. S3, which is available at http://www
.jem.org/cgi/content/full/jem.20061198/DC1). Instead, as 
with the in vitro experiments, these studies demonstrate that 
IL-2 production is suppressed when T cells are primed in an 
IL-2–rich environment.
To investigate the long-term eff   ects of IL-2 treat-
ment on IL-2 production, WT mice were populated with 
DO11+CD4+ cells, immunized, and treated with IL-2 as de-
scribed above. However, instead of analyzing the response 
at day 5 after immunization, when cells had recently been 
exposed to antigen and high doses of IL-2, LNs and spleens 
were isolated at day 15 after immunization, when T cell re-
sponses had contracted and levels of antigen, costimulation, 
and IL-2 were greatly diminished. As above, immunization 
of control and IL-2–treated animals led to increases in pri-
mary lymphoid organ cellularity and absolute numbers of 
DO11+ cells. However, unlike the earlier time point, both 
groups were fully capable of producing IL-2 when stimulated 
ex vivo (Fig. 5, F and G, and Fig. S4, which is available at 
http://www.jem.org/cgi/content/full/jem.20061198/DC1). 
In the context of the preceding observations, these studies 
imply that the eff  ects of IL-2 on helper T cell IL-2 produc-
tion are transient, likely requiring continued availability of 
the cytokine.
Because of its central role in the life and death of helper 
T cells, the need to regulate IL-2 has long been appreciated. 
However, although the stimuli that induce IL-2 production 
are well understood (20), there is no consensus on why this 
process is so short-lived. The present studies elaborate on the 
latter issue by characterizing a negative feedback loop that is 
necessary and suffi     cient to limit IL-2 production during 
helper T cell diff  erentiation. Not only do these fi  ndings es-
tablish IL-2 as a potent IL-2 inhibitor, they also demonstrate, 
together with previous work (18), that this property is shared 
by other common γ chain cytokines (IL-4 and IL-7) and se-
lect members of the IL-6/IL-12 family (IL-12 and IL-27). 
Each can suppress individually, albeit with varying potencies 
(IL-2>IL-4>IL-27>IL-12>IL-7), but the most effi   cient 
IL-2 inhibition is seen when two or more of these cytokines 
are combined. Given this synergy, it can now be proposed 
that, depending on the infl  ammatory conditions present at 
the time of priming, T cell IL-2 production is limited by a 
combination of negative feedback and cytokine-dependent 
inhibition (Fig. S5, available at http://www.jem.org/cgi/
content/full/jem.20061198/DC1). However, it should be 
emphasized that this regulatory network curtails the duration 
of IL-2 production but does not aff  ect the initial, antigen-
driven signals that induce the response. As a result, there will 
always be a short burst of IL-2 that precedes the suppression, 
thus guaranteeing a brief exposure to this growth factor. 
Consistent with that idea, cytokine-dependent IL-2 inhibi-
tion is not seen when T cells are cultured in vitro for <24 h 
or when their proliferation is arrested (Fig. S6). Therefore, 
while providing a cellular and molecular rationale for its 
  transient pattern of expression, the data presented here are con-
sistent with established models that hold that IL-2 production 
is required for the expansion, survival, and or diff  erentiation 
of clonotypic T cells (2, 3, 12). Moreover, they are in accor-
dance with studies showing that rapid epigenetic changes 
Figure 5.  IL-2 can suppress IL-2 responses after immunization. 
(A–E) CFSE-labeled, DO11.10+ CD4+ T cells were transferred into WT mice, 
which were immunized 2 d later with antigen-pulsed DCs. At days 2 and 
3 after immunization, mice were treated with PBS or IL-2, and 2 d later 
(day 5 after immunization), LNs and spleens were isolated. (A) Lymphocytes 
and splenocytes were enumerated by microscopy. Percentages of 
DO11.10+ CD4+ T cells were determined by fl  ow cytometry and used to 
calculate the absolute number of antigen-specifi  c cells. (B and C) Surface 
CD25 was measured directly ex vivo. (D and E) Intracellular IL-2 was 
measured after restimulation with either (D) OVA-pulsed DCs (16 h) or 
(E) PMA/ionomycin (4 h). Gray numbers are the percentage of undivided IL-2+ 
cells, whereas the back numbers denote the percentage of proliferating 
IL-2+ cells (two mice per group; three experiments pooled in A and B). 
(F and G) WT mice were populated with DO11.10+ CD4+ T cells, immunized, 
and treated with IL-2 as above. LNs and spleens were processed at 15 d 
after immunization (three mice per group; two experiments pooled in 
F and G). (A–H) For cytokine analysis, all groups were treated with 
BFA for 2 h before intracellular staining. Only CD4+ DO11.10+ events 
are displayed.70  IL-2 PRODUCTION IS LIMITED BY CYTOKINE/STAT SIGNALS | Villarino et al.
promote IL-2 gene accessibility and transcription before cell 
cycle entry (21).
The studies presented here establish that STAT5 is required 
for IL-2 and IL-4 to inhibit helper T cell IL-2 production. 
In addition, they implicate other STAT family members 
in this process, namely STAT6 and STAT4. Whether all of 
these STAT signals converge on a single inhibitory mecha-
nism remains to be determined, but because there is no evi-
dence that STATs bind the IL-2 promoter and directly 
obstruct gene expression, it is likely that they induce addi-
tional factors that, in turn, act as transcriptional repressors. 
Consistent with this hypothesis, it has long been known that 
blocking protein synthesis during T cell diff  erentiation results 
in super-induction of IL-2 mRNA (22). Several nuclear pro-
teins, like Tob and p27kip1, have been shown to prohibit IL-2 
production in anergic T cells, and it is possible that analo-
gous mechanisms are used during eff  ector T cell responses 
(23, 24). On the other hand, the culture conditions used here 
do not induce anergy, and it is just as likely that cytokine-
  dependent IL-2 inhibition does not invoke anergy-related 
pathways. Furthermore, given that IL-2 production can be 
regulated by changes in mRNA stability (25), it is also possi-
ble that cytokine-dependent inhibition is a posttranscrip-
tional phenomenon.
Aside from the STAT-dependent mechanism described 
here, many factors are known to suppress IL-2 production. 
These observations support the idea that IL-2 responses 
are tightly regulated, but the relationship between STAT-
dependent inhibition and other “IL-2 inhibitors” remains 
unclear. Various regulatory pathways may work together to 
limit IL-2 or, alternatively, each may operate independently. 
Consistent with the latter idea, NF-κBp50 and Tbet have 
been shown to suppress IL-2 production (26, 27), but, in 
their absence, IL-2, IL-4, and IL-12 are still potent inhibitors 
(unpublished data and 18). Even so, this result does not ex-
clude the possibility that STAT-dependent signals cooperate 
with other factors, such as TGF-β/Smad3, CTLA-4, and 
BTLA, all of which are known to suppress IL-2 production 
(28, 29). Whatever the case, it is likely that this process is al-
ways limited by STAT-dependent means and, as such, it can 
now be proposed that helper T cells are “hard-wired” to pro-
duce all of the IL-2 they need as a short burst after activation. 
This idea is supported by a recent study demonstrating that 
brief exposure to IL-2 during priming is both necessary and 
suffi   cient to potentiate memory CD8+ T cell responses (30). 
Coupled with this present study, those data argue that, al-
though essential, IL-2 responses are meant to be brief. Given 
this new insight, suppressive eff  ects on helper T cell IL-2 
production must be considered as clinical applications for cy-
tokines are explored.
MATERIALS AND METHODS
Mice. WT C57B/6 mice were purchased from The Jackson Laboratory. 
Mice lacking STAT5a/b were generated as described previously (16) and, 
along with littermate controls (C57B/6 background), were provided by 
J. O’Shea and L. Hennighausen (NIH). In brief, mice were engineered with 
LoxP sites fl  anking both STAT5 genes, and then bred with transgenic 
  animals expressing Cre recombinase under control of the CD4 promoter. 
The resulting off  spring lacked STAT5a and STAT5b in all CD4+ T cells 
with >90% deletion effi   ciency (Fig. S2). The offi   cial nomenclature for these 
conditional knockout mice is Stat5fl x, cd4 cre (16), but, for simplicity, they are 
referred to here as STAT5−/−. Mice defi  cient in STAT4 (STAT4−/−) and 
STAT6 (STAT6−/−) were purchased along with the corresponding BALB/c 
WT controls from The Jackson Laboratory. Transgenic mice (BALB/c) 
  expressing the DO11.10 αβTCR-specifi   c for chicken OVA peptide 
(OVA323–339) in the context of MHC class II molecule I-Ad were generated 
by K. Murphy (Washington University, St. Louis, MO) and provided by 
A.A.K. Abbas (University of California, San Francisco, San Francisco, CA). 
All experiments were performed according to the guidelines of the University 
of Pennsylvania Institutional Animal Care and Use Committee.
In vitro T cell diff  erentiation. For polyclonal studies, splenocytes were 
isolated from WT or STAT-defi   cient mice and depleted of CD8+ and 
NK1.1+ cells by magnetic bead separation (Polysciences Inc.). 2 × 106/ml 
cells were then labeled with 5 μg/ml CFSE (Sigma-Aldrich) and stimulated 
with 1 μg/ml of soluble anti-CD3 (clone 17A2) and 1 μg/ml anti-CD28 
antibodies (clone 37.51; both were either generated in house or purchased 
from eBioscience). Where stated, cultures were supplemented with 10 μg/ml 
of monoclonal, anti-murine IL-2 antibodies (clones S4B6 or JES6-1; generated 
in house or from eBioscience) and/or the following cytokines: 1, 10, 50, 
or 100 U/ml of human IL-2 (NIH/NCI BRB Preclinical Repository), 
50 ng/ml of murine IL-4 (eBioscience), 10 ng/ml murine IL-7 (eBioscience), 
5 ng/ml of murine IL-12 (Genetics Institute), or 10 ng/ml of murine IL-15 
(eBioscience). 10 μg/ml anti-murine IL-4 was used in one set of experi-
ments (clone 11B11; NIH/NCI BRB Preclinical Repository).
For antigen-specifi   c studies, spleens and LNs were isolated from 
DO11.10 transgenic mice. CD4+ T cells were isolated using positive selec-
tion beads (Dynal), CFSE labeled, and stimulated with WT syngeneic, 
  mitomycin C–treated splenocytes in the presence of 100 ng/ml OVA 
  peptide (2.5 × 106 mito-APCs vs. 0.25 × 106 DO11.10 CD4+ T cells).
Flow cytometry. To assay in vitro cytokine production, CD4+ T cells 
were cultured for 24, 48, 72, or 96 h and pulsed with 50 ng/ml PMA 
(Sigma-Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich). 2 h later, cells 
were treated with brefeldin A (BFA; 2 h at 10 μg/ml; Sigma-Aldrich) and 
stained for intracellular IL-2 in combination with surface CD4 (eBioscience). 
Rectangular gates indicate specifi   c IL-2 staining compared with control 
mAb. Percentages of IL-2+ CD4+ cells are displayed within or beside their 
corresponding gates, and MFIs of IL-2+ events are presented vertically. For 
detection of phsopho-STAT4, phospho-STAT6, and FoxP3, intracellular 
staining was performed according to the manufacturer’s specifi  cations (kits 
by eBioscience).
Immunizations. For immunizations, bone marrow–derived DCs (BMDCs) 
were generated from WT BALB/c mice. In brief, marrow was isolated, 
  depleted of red blood cells, and cultured with GM-CSF to enrich for DCs 
(7 d), which were then matured (IL-4 plus LPS) and loaded with 1 μg/ml 
OVA peptide (>70% MHCIIhighB7.2high by fl  ow cytometry). In corre-
sponding preparations, 2 × 106 CFSE-labeled, DO11.10 CD4+ T cells were 
adoptively transferred (intravenous) into WT BALB/c recipients that were 
immunized 72 h later with the mature BMDCs. At days 2 and 3 after immu-
nization, mice were treated (intraperitoneal) with either PBS (control) or re-
combinant human IL-2 (0.8 × 106 U/dose in 800 μl PBS). LNs and spleens 
were isolated 2 (day 4 after immunization) or 12 (day 15 after immunization) 
d later, and surface staining for CD4, DO11 TCR, and CD25 was per-
formed directly ex vivo. For each mouse, absolute numbers of antigen-
  specifi  c cells were calculated with the following formula: (percentage of 
CD4+DO11+ cells × total cellularity of LNs or spleens)/100 = total 
CD4+DO11+ cells. IL-2 production was assayed after lymphocytes/splenocytes 
were stimulated with either PMA/ionomycin (4 h) or mature BMDCs (16 h; 
10:1 lymphocyte/splenocyte/DC ratio). All groups were treated with BFA 
for 2 h before intracellular cytokine staining.JEM VOL. 204, January 22, 2007  71
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Real-time PCR. mRNA was isolated from cultured cells (no PMA/Iono/
BFA) using Trizol reagent and converted to cDNA using SuperScript II 
reverse transcriptase (300–400 ng RNA per reaction; Invitrogen). For real-
time PCR, IL-2–specifi  c primers and probes were purchased from Applied 
Biosystems, and amplifi  cation was performed according to the manufacturer’s 
specifi  cations. IL-2 mRNA levels were normalized with respect to ubiqui-
tous 18S ribosomal mRNA, and expression of IL-2 is represented as the fold 
induction over naive (unstimulated) controls.
Statistics. Statistical variations between experimental groups were deter-
mined by two-tailed, paired Student’s t test. Signifi  cant diff  erences, P < 0.05, 
are denoted by an asterisk. Error bars denote standard deviations.
Online supplemental material. Fig. S1 shows that the auto-inhibitory 
properties of IL-2 are not dependent on T reg cells. Fig. S2 shows that IL-2 
production is not transient in the absence of STAT5. Fig. S3 illustrates that 
treatment with IL-2 does not enhance the expansion of T reg cells after 
  immunization. Fig. S4 shows that treatment with IL-2 does not impose a 
permanent block on helper T cell IL-2 production after immunization. Fig. 5 
is a model for the regulation of IL-2 production during primary helper T cell 
responses, and Fig. S6 displays temporal and cell cycle requirements for in-
hibiting IL-2 production. The online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20061198/DC1.
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